Precisely, the biomarkers should allow ariad to target those pts who have mutations that are not likely to respond to Pfizer's Crizotinib. Thanks for clearing up any confusion.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.